CD19 and leukemia: Zhang et al. published the result of a phase 1/2 study using anti-CD19 CAR T cells to treat patients with R/R B-ALL, including those with high-risk features such as BCR-ABL fusion gene, TP53 mutation (12 patients), extramedullary disease (EMD) (including central nervous system [CNS] leukemia), and those who relapsed after allo-SCT (16 patients) [43].